ECM-BMP Bone Regeneration Inducer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inducers for bone regeneration, such as living tissues, growth factors, and extracellular matrix (ECM), face limitations including limited sources, high costs, and insufficient bone regeneration capacity, particularly in the absence of soft tissues.
Innovation Solution
A combination of ECM and bone morphogenetic protein (BMP) is used as a regeneration inducer, where ECM is derived from animal or non-animal tissues, treated through methods like lyophilization and cross-linking, and administered as a gel to promote bone and soft tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If living tissues (nail bed or germ) are used as inducers, then bone regeneration can be induced, but the source is limited and immune rejection occurs
Solution Approach 1:
The patent uses decellularized extracellular matrix (ECM) as a copy or substitute for living tissues. The ECM is derived from animal or non-animal sources, processed to remove cells, and retains the structural and biochemical cues necessary to induce bone regeneration without the limitations of living tissue sources or immune rejection concerns.
Solution Approach 2:
The patent employs ECM that can be derived from abundant, inexpensive sources such as animal tissues. The ECM is processed into a form that can be applied as a single-use inducer, eliminating the need for expensive, limited-source living tissues while avoiding immune rejection issues.
2Reliability
If growth factors (BMPs) are used as inducers, then bone regeneration is promoted, but the cost is high and regeneration is limited to specific bone mass
Solution Approach 1:
The patent combines ECM with BMPs to create a synergistic system. The ECM provides a structural framework and biochemical environment that enhances BMP activity, allowing for more extensive bone regeneration than BMP alone while potentially reducing the amount of BMP needed, thus addressing both the quantity and cost limitations.
3Adaptability or versatility
If ECM is used as inducer, then soft tissue regeneration is supported, but bone regeneration effect is weak and the amount of regenerated tissue is too small
Solution Approach 1:
The patent merges ECM with BMPs to create a dual-function inducer. The ECM provides the structural support and soft tissue regeneration capabilities, while the added BMPs significantly enhance bone regeneration. This combination allows the system to overcome the weak bone regeneration effect of ECM alone while maintaining its soft tissue regeneration advantages.
4Ease of operation
If bone is truncated shorter than soft tissue during amputation, then soft tissue coating is achieved, but bone regeneration without soft tissue is insufficient
Solution Approach 1:
The patent uses ECM-BMP composite as an intermediary substance applied directly to the bone stump. This intermediary provides the necessary biochemical and structural cues to induce robust bone regeneration even when soft tissue coating is not present, eliminating the need to truncate bone shorter than soft tissue and allowing for more aggressive bone regeneration in cases where soft tissue is absent or damaged.
Data Source
Figure 1
Figure 2-1~2-2
Figure 3-1~3-3
AI summary
An inducer is directed to the induction of in situ regeneration in regenerative medicine. The inducer including an extracellular matrix and/or a bone morphogenetic protein, can induce the regeneration of bone and soft tissues surrounding the bone such as muscle, blood vessel and skin at the residual tissues where trauma occurs. The amount of regenerated tissue is associated with the dose of the implanted inducer.